Navigation Links
Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
Date:12/18/2007

HOPKINTON, Mass., Dec. 18 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc., (Nasdaq: ALSE), announced today that it has enrolled the first subject in the initial stage of the ALTROPANE(R) Parkinson's or Essential Tremor - 2 (POET-2) Phase III clinical trial program. This subject was enrolled at the University of Alabama, Birmingham trial site under the direction of Principal Investigator Dr. Ray L. Watts, MD, Professor and Chairman of the Department of Neurology.

ALTROPANE is a diagnostic molecular imaging agent being developed to aid in the differentiation of Parkinsonian Syndromes from non-Parkinsonian tremor. An estimated 10 million Americans are presently living with tremor. Currently, tremor disorders are diagnosed by subjective clinical evaluation which, according to the Canadian Journal of Neuroscience, is associated with an error rate among general neurologists of 25% to 35%.

Dr. Mark Hurtt, the Company's Chief Medical Officer, commented, "The enrollment of the first subject in the POET-2 Phase lll program is an important milestone for Alseres as we continue the process of moving ALTROPANE toward regulatory approval. We believe that ALTROPANE has the potential to help doctors more accurately diagnose tremor to minimize the side-effects of unnecessary treatments. ALTROPANE may also provide diagnostic support to monitor disease progression and the effects of emerging therapeutics."

Dr. Ray L. Watts, M.D. of University of Alabama -- Birmingham, Movement Disorder Specialist, stated "ALTROPANE may prove to be a valuable tool in assisting neurologists with their clinical diagnosis of Parkinsonian Syndromes, especially in the early stages."

About the "Parkinson's or Essential Tremor" (POET-2) Trial Program

The POET-2 program is a two-part registration program that will begin with a clinical study in subjects in up to 15 centers to acquire a set of ALTROPANE images which will be used to train the expert readers as is the customary requirement for clinical trials of molecular imaging agents. The second part of the planned POET-2 program involves two concurrent, multi-center Phase III trials of approximately 150 subjects each using the optimized ALTROPANE imaging protocol developed for commercial use.

About ALTROPANE Imaging Agent and Parkinsonian Syndromes (PS) Including Parkinson's Disease

ALTROPANE is a molecular imaging agent that specifically binds to the dopamine transporter (DAT) protein found on the surface of dopamine-producing neurons, making it visible during Single Photon Emission Computed Tomography or "SPECT" imaging. Since most forms of Parkinsonian Syndromes result in a decreased number of dopamine-producing cells, it would be expected that these patients also have fewer DATs than do patients without Parkinsonian Syndromes. Thus, we believe that ALTROPANE used in conjunction with SPECT imaging could be a useful test to distinguish Parkinsonian Syndrome tremors from non- Parkinsonian tremor: non-Parkinsonian patients would have more ALTROPANE- binding visible in the SPECT image, while Parkinsonian patients would have less.

There are several conditions that are considered Parkinsonian Syndromes. Parkinson's Disease is the most common form of Parkinsonian Syndrome. Other less common Parkinsonian Syndromes include multiple system atrophy (MSA), Progressive Supranuclear Palsy (PSP), and drug-induced Parkinsonism.

The International Essential Tremor Foundation estimates that as many as 10 million people in the United States are afflicted by essential tremor. Experts estimate that, each year, approximately 140,000 individuals present to their physician with new, undiagnosed movement disorders such as Parkinson's Disease and Essential Tremor. In 2002, the European Journal of Neurology reported that there is a 20- to 30-percent misdiagnosis rate in the early stages of Parkinson's disease. Other publications have reported even higher rates of misdiagnosis. We believe that the accurate differentiation of Parkinsonian from non-Parkinsonian tremors could have important clinical implications. Physicians may be able to initiate earlier referral for specialty care, prescribe effective treatments, and provide a more-informed prognosis for patients and their families. If these trials are successful and the drug is approved, we believe that ALTROPANE could be a highly-selective central nervous system diagnostic molecular imaging agent -- and a valuable tool to help clinicians make better, more-accurate diagnoses.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) is a biotechnology company engaged in developing breakthrough regenerative therapeutics to treat traumatic injuries and degenerative diseases. The Company maintains a world- class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin(R), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. The Company's lead molecular imaging product candidate is ALTROPANE(R) which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

ALTROPANE is a registered trademark of Alseres Pharmaceuticals, Inc.

Safe Harbor:

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres Pharmaceuticals' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the Company's clinical development and trials for ALTROPANE, the prospects of FDA approval of ALTROPANE and the commercialization, including partnering opportunities, of ALTROPANE. Forward- looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres Pharmaceuticals from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres Pharmaceuticals is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

Contact: Sharon Correia

Director, Corporate Communications

scorreia@alseres.com

508-497-2360 ext. 224


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Bernstein Liebhard LLP today announced that a securities class ... for the District of Arizona on ... or entities who purchased common shares of Insys Therapeutics Inc. ... 3, 2015 through January 25, 2016 (the "Class Period").  The ... of the Securities Exchange Act of 1934.  ...
(Date:2/4/2016)... , Feb. 4, 2016 Global Immunology ... market to drive long-term market growth Summary ... set of chronic disorders that affect 5–7% of ... terms of their symptoms and key patient demographics, ... of immune pathways and an inappropriate immune response. ...
(Date:2/4/2016)... SPRING, Md. , Feb. 4, 2016 In ... Califf , the FDA,s Deputy Commissioner for Medical Products and ... action plan to reassess the agency,s approach to opioid medications. ... epidemic, while still providing patients in pain access to effective ... The FDA will: , Re-examine the risk-benefit paradigm ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held last ... Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred ... Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served APDA ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Stuart ... tattoo technology, the PicoSure. Designed to provide the most effective tattoo removal today, Dr. ... with unmatched results. , Developed by Cynosure, the PicoSure has been approved by the ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is ... one drop zone to the next using Colorize's dynamic moving camera. Colorize is perfect ... package includes a 3D slideshow environment with 1 to 5 focus points per scene, ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Health and wellness ... relevant to individuals in the event they are experiencing an illness. Migraines are a ... Americans that are afflicted with migraines would not wish the pain on their worst ...
(Date:2/5/2016)... ... 2016 , ... On June 9-10, Las Vegas will host ... (CME) event presented by the Association for Comprehensive Care in Rare Diseases (ACCORD). ... mission is to provide education, tools, and resources to primary care clinicians that ...
Breaking Medicine News(10 mins):